🔎 Trials Near Me

Beranda › Kanker Saluran Empedu › Kentucky

Uji klinis Kanker Saluran Empedu di Kentucky

6 studi untuk Kanker Saluran Empedu mencari peserta di lokasi di Kentucky.

Kota di Kentucky

Teks studi resmi (Bahasa Inggris)

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  • Research Site, Louisville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06219941

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  • Norton Cancer Institute (Site 115), Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07265674

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

  • Norton Cancer Institute, Louisville
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05482893

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Research Site, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07221253

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  • Norton Cancer Institute - Audubon, Louisville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06282575

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • St. Elizabeth Healthcare, Edgewood
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.